Targeting MCL-1 directly with selective inhibitors, or indirectly with agents that cause downregulation of MCL-1 as part of their mechanism of action, proved to be efficient in numerous preclinical models of B-NHL, including DLBCL, MCL, BL or CLL [105,106,107,108,109]. The gene discussed is MCL1; the disease is diffuse large B-cell lymphoma.